Document is current

Article History

Accepted: 21 January 2025

First Online: 25 February 2025

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: Arexvy is a trademark owned by or licensed to GSK. Abrysvo is a trademark of Pfizer Inc. mRESVIA is a trademark of Moderna.

: YP, PS, LH and JPM are employees of GSK and hold financial equities in GSK. EB, MEG, JLRA are employees of P95. GB received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Boehringer-Ingelheim, Chiesi, GSK, MSD, Novartis, Sanofi Regeneron. GB is President of the Belgian Respiratory Society. GR’s institution received support from CAPNETZ foundation. GR reports personal fees from Astra Zeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis and Pfizer for consultancy during advisory board meetings and from from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures including service on speakers bureaus. GR is the Chairman of CAPNETZ executive board. All authors declare no other financial or non-financial interests, relationships or activities. AF receives institutional research grant from Janssen, Merck, CyanVac, VaxCo, BioFire Diagnostics, Moderna, Pfizer; AstraZeneca, Sanofi Pasteur, receives consulting fees from ADMA Biologics, GSK, Sanofi Pasteur; receives payment for support for attending meetings and/or travel from GSK, Moderna, Sanofi Pasteur; participates on the Data Safety Monitoring Board or Advisory Board of Novovax.